|
1
|
Baraban SC: Neuropeptide Y and limbic
seizures. Rev Neurosci. 9:117–128. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cerdá-Reverter JM and Larhammar D:
Neuropeptide Y family of peptides: Structure, anatomical
expression, function, and molecular evolution. Biochem Cell Biol.
78:371–392. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Silva AP, Cavadas C and Grouzmann E:
Neuropeptide Y and its receptors as potential therapeutic drug
targets. Clin Chim Acta. 326:3–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuo LE, Kitlinska JB, Tilan JU, Li L,
Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R,
et al: Neuropeptide Y acts directly in the periphery on fat tissue
and mediates stress-induced obesity and metabolic syndrome. Nat
Med. 13:803–811. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baldock PA, Allison SJ, Lundberg P, Lee
NJ, Slack K, Lin EJ, Enriquez RF, McDonald MM, Zhang L, During MJ,
et al: Novel role of Y1 receptors in the coordinated regulation of
bone and energy homeostasis. J Biol Chem. 282:19092–19102. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang K, Guan H, Arany E, Hill DJ and Cao
X: Neuropeptide Y is produced in visceral adipose tissue and
promotes proliferation of adipocyte precursor cells via the Y1
receptor. FASEB J. 22:2452–2464. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khor EC and Baldock P: The NPY system and
its neural and neuroendocrine regulation of bone. Curr Osteoporos
Rep. 10:160–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Horsnell H and Baldock PA: Osteoblastic
actions of the neuropeptide Y system to regulate bone and energy
homeostasis. Curr Osteoporos Rep. 14:26–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin S, Boey D and Herzog H: NPY and Y
receptors: Lessons from transgenic and knockout models.
Neuropeptides. 38:189–200. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Allison SJ, Baldock PA and Herzog H: The
control of bone remodeling by neuropeptide Y receptors. Peptides.
28:320–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baldock PA, Sainsbury A, Couzens M,
Enriquez RF, Thomas GP, Gardiner EM and Herzog H: Hypothalamic Y2
receptors regulate bone formation. J Clin Invest. 109:915–921.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi YC, Lin S, Wong IP, Baldock PA,
Aljanova A, Enriquez RF, Castillo L, Mitchell NF, Ye JM, Zhang L,
et al: NPY neuron-specific Y2 receptors regulate adipose tissue and
trabecular bone but not cortical bone homeostasis in mice. PLoS
One. 5:e113612010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lundberg P, Allison SJ, Lee NJ, Baldock
PA, Brouard N, Rost S, Enriquez RF, Sainsbury A, Lamghari M,
Simmons P, et al: Greater bone formation of Y2 knockout mice is
associated with increased osteoprogenitor numbers and altered Y1
receptor expression. J Biol Chem. 282:19082–19091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Igwe JC, Jiang X, Paic F, Ma L, Adams DJ,
Baldock PA, Pilbeam CC and Kalajzic I: Neuropeptide Y is expressed
by osteocytes and can inhibit osteoblastic activity. J Cell
Biochem. 108:621–630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kurebayashi N, Sato M, Fujisawa T,
Fukushima K and Tamura M: Regulation of neuropeptide Y Y1 receptor
expression by bone morphogenetic protein 2 in C2C12 myoblasts.
Biochem Biophys Res Commun. 439:506–510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee NJ, Nguyen AD, Enriquez RF, Doyle KL,
Sainsbury A, Baldock PA and Herzog H: Osteoblast specific Y1
receptor deletion enhances bone mass. Bone. 48:461–467. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bjurholm A, Kreicbergs A, Schultzberg M
and Lerner UH: Parathyroid hormone and noradrenaline-induced
enhancement of cyclic AMP in a cloned osteogenic sarcoma cell line
(UMR 106) is inhibited by neuropeptide Y. Acta Physiol Scand.
134:451–452. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakashima A, Katagiri T and Tamura M:
Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2)
signaling in differentiation pathway of C2C12 myoblasts. J Biol
Chem. 280:37660–37668. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uyama M, Sato MM, Kawanami M and Tamura M:
Regulation of osteoblastic differentiation by the proteasome
inhibitor bortezomib. Genes Cells. 17:548–558. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iizuka S, Oridate N, Nashimoto M, Fukuda S
and Tamura M: Growth inhibition of head and neck squamous cell
carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE
gene silencing. PLoS One. 9:e1141212014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karsenty G: Transcriptional control of
skeletogenesis. Annu Rev Genomics Hum Genet. 9:183–196. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teixeira L, Sousa DM, Nunes AF, Sousa MM,
Herzog H and Lamghari M: NPY revealed as a critical modulator of
osteoblast function in vitro: New insights into the role of Y1 and
Y2 receptors. J Cell Biochem. 107:908–916. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matic I, Matthews BG, Kizivat T, Igwe JC,
Marijanovic I, Ruohonen ST, Savontaus E, Adams DJ and Kalajzic I:
Bone-specific overexpression of NPY modulates osteogenesis. J
Musculoskelet Neuronal Interact. 12:209–218. 2012.PubMed/NCBI
|
|
25
|
Ryoo HM, Lee MH and Kim YJ: Critical
molecular switches involved in BMP-2-induced osteogenic
differentiation of mesenchymal cells. Gene. 366:51–57. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sousa DM, Baldock PA, Enriquez RF, Zhang
L, Sainsbury A, Lamghari M and Herzog H: Neuropeptide Y Y1 receptor
antagonism increases bone mass in mice. Bone. 51:8–16. 2012.
View Article : Google Scholar : PubMed/NCBI
|
